Event Data
{"article_title":"SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules: Synthesis and algorithms.","author":"Borson-Chazot F, Buffet C, Decaussin-Petrucci M, Cao CD, Drui D, Leboulleux S, Leenhardt L, Menegaux F, Pattou F, Lussey-Lepoutre C","journal_title":"Annales d'endocrinologie","issn":"2213-3941","isbn":"","publication_date":"2022-12-01","volume":"83","issue":"6","first_page":"440","page_count":"","accession_number":"36336101","doi":"10.1016\/j.ando.2022.11.001","publisher":"Elsevier","doctype":"Practice Guideline","subjects":"Thyroid Nodule diagnosis; Thyroid Nodule therapy; Thyroid Nodule pathology; Nuclear Medicine; Endocrinology; Thyroid Neoplasms diagnosis; Thyroid Neoplasms therapy; Thyroid Neoplasms pathology; Humans; Consensus; Algorithms","interest_area":["Endocrinology"],"abstract":"The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid with benign and non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment. The diagnosis and treatment of thyroid nodules requires close collaboration between endocrinologists, nuclear medicine physicians and surgeons but also involves other specialists. Therefore, this consensus statement was established jointly by 3 societies, the French Society of Endocrinology (SFE), the French Association of Endocrine Surgery (AFCE) and the French Society of Nuclear Medicine (SFMN); the various working groups included experts from other specialties (pathologists, radiologists, pediatricians, biologists, etc.). This specific text is a summary chapter taking up the recommendations from specific sections and presenting algorithms for the exploration and management of thyroid nodules. Copyright \u00a9 2022 Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=36336101","isPdfLink":true,"isSAML":false,"an":"36336101","number_other":"","type_pub":"","issn_electronic":"2213-3941","languages":"English","language":"eng","date_entry":"Date Created: 20221106 Date Completed: 20221216 Latest Revision: 20231129","date_update":"20240105","titleSource":"Annales d'endocrinologie [Ann Endocrinol (Paris)] 2022 Dec; Vol. 83 (6), pp. 440-453. Date of Electronic Publication: 2022 Nov 04.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-12-01","description":"The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid with benign and non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment. The diagnosis and treatment of thyroid nodules requires close collaboration between endocrinologists, nuclear medicine physicians and surgeons but also involves other specialists. Therefore, this consensus statement was established jointly by 3 societies, the French Society of Endocrinology (SFE), the French Association of Endocrine Surgery (AFCE) and the French Society of Nuclear Medicine (SFMN); the various working groups included experts from other specialties (pathologists, radiologists, pediatricians, biologists, etc.). This specific text is a summary chapter taking up the recommendations from specific sections and presenting algorithms for the exploration and management of thyroid nodules.<br \/> (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=edb&AN=36336101&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Borson-Chazot F, Buffet C, Decaussin-Petrucci M, Cao CD, Drui D, Leboulleux S, Leenhardt L, Menegaux F, Pattou F, Lussey-Lepoutre C","additionalInfo":{"Authored_By":"Ghoneim, Asser","Published_Date":"2009-01-01","Source":"Naunyn-Schmiedeberg's Archives of Pharmacology; Jan2009, Vol. 379 Issue 1, p47-60, 14p, 1 Chart, 7 Graphs","Languages":"English","Title_Abbreviations":"Naunyn-Schmiedeberg's Archives of Pharmacology","Volume":"379"},"header":{"DbId":"edb","DbLabel":"Complementary Index","An":"36336101","RelevancyScore":"833","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"833.468627929688"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=edb&AN=36336101&authtype=shib&custid=ns346513&group=main&profile=eds"}
Description
Ethanol-induced hepatocyte necrosis and apoptosis are valid in vitro models to investigate the modulatory effects of hepatoprotective/toxic agents such as curcumin. In this study, suspension and monolayer cultures of isolated rat hepatocytes were used. Levels of trypan blue uptake, reduced glutathione, and lipid peroxidation were quantified. Chromatin condensation, caspase-3 activity, and cytochrome c extramitochondrial translocation were also evaluated. Results revealed that curcumin did not protect against either ethanol-induced necrosis or glutathione depletion. Neither did curcumin reduce caspase-3 activation nor chromatin condensation. In contrast, curcumin induced glutathione depletion, caspase-3 activation, necrosis, and apoptosis. Fortunately, all tested curcumin concentrations (1 μM–10 mM) diminished the ethanol-induced lipid peroxidation. In addition, 1 μM curcumin decreased cytochrome c translocation in hepatocyte monolayers. In conclusion, low concentrations of curcumin may protect hepatocytes by reducing lipid peroxidation and cytochrome c release. Conversely, higher concentrations provoke glutathione depletion, caspase-3 activation, and hepatocytotoxicity. [ABSTRACT FROM AUTHOR]
